Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. [electronic resource]
Producer: 20130205Description: 6079-88 p. digitalISSN:- 1097-0142
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Cost-Benefit Analysis
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Quality-Adjusted Life Years
- Rituximab
- SEER Program
- Survival Rate
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.